Bayer HealthCare chief Fibig departs for CEO post; China fines J&J, B&L for price-fixing;

@FiercePharma: ICYMI: Yesterday's full issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Article | Follow @TracyStaton

@CarlyHFierce: Our newest special report is here! Top 10 best-selling cancer drugs of 2013, just in time for #ASCO14. Feature | Follow @CarlyHFierce

> Bayer HealthCare President Andreas Fibig is jumping ship to take on the CEO job at International Flavors & Fragrances; Bayer says a replacement will be named in a few days. Report

> China fined Johnson & Johnson ($JNJ) and the Valeant Pharmaceuticals ($VRX) unit Bausch & Lomb for alleged price-fixing on eye-care products. Report

> U.S. traders' ignorance of U.K. takeover rules spawned confusion amid Pfizer's ($PFE) $117 billion play for AstraZeneca ($AZN). Report

> Pittsburgh-based generics maker Mylan ($MYL) rolled out its version of Malarone, the GlaxoSmithKline ($GSK) malaria treatment, in the U.S. Release

> Merck Serono launched a web-based software system that can track patients' injections of its multiple sclerosis treatment Rebif. Report

Medical Device News

@FierceMedDev: St. Jude to take over CardioMEMS following FDA approval. News | Follow @FierceMedDev

@VarunSaxena2: Who wants to read the UK Takeover Code with me? Wondering if the FT story counts as a "statement." More (PDF) | Follow @VarunSaxena2

@MichaelGFierce: ICYMI yesterday from FierceDrugDelivery: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Story | Follow @MichaelGFierce

@EmilyWFierce: Top 10 best-selling cancer drugs brought in between $1.7B and $7.8B in 2013, with Roche's Rituxan leading the pack. More | Follow @EmilyWFierce

> FDA clears nonsurgical treatment for male urinary and fecal incontinence. More

> Stryker CEO clears the air regarding Smith & Nephew deal. Story

> Medtronic shells out $9.9M to settle physician kickback claims. Article

Biotech News

@FierceBiotech: Tune in today for an #ASCO14 chat w/ @JohnCFierce & @PennMedicine's David Porter at 3:30 EST. More info | Follow @FierceBiotech

@JohnCFierce: So now it's $GSK that's supposed to want to buy $ARIA? Any bets on the next big pharma in this particular rumor mill? | Follow @JohnCFierce

@DamianFierce: From BMO's survey of $AGN shareholders: How will $AGN's business be in 3 years if $VRX buys it? Table | Follow @DamianFierce

@EmilyMFierce: Popular at FierceBiotechResearch.com : #Antisense compound may provide new #Alzheimers treatment. Story | Follow @EmilyMFierce

> Trimel wins FDA approval for its 'low-T' nasal gel. Item

> ASCO: Big Four immuno-oncology players wager $1.3B on next-gen cancer drugs. Report

> Rodin bags a $12.9M A round to think big about CNS therapies. News

> Lilly steps out of its comfort zone, backs an international biotech fund. Article

Pharma Manufacturing News

> Actavis commits $48M to revitalizing Puerto Rico plants. More

> Hospira plans $120M investment in Kansas facility. Item

> Lilly, Merck juggle cost and complexity in manufacturing strategies. Report

> FDA circles Wockhardt's Illinois plant as earlier sanctions slash sales. More

> Hikma lined up as potential buyer of troubled Ben Venue plant. Story

> FDA puts improved generic evaluations on $50M regulatory wishlist. Article

Vaccines News

> Pfizer teams up to lift adult vaccination rates--and Prevnar sales, too. News

> Study: Only 50% of Canadian healthcare workers are vaccinated. Story

> ASCO preview: What's the outlook for cancer vaccines? Report

> Study: Moral concerns lead barriers to Gardasil uptake in college freshmen. More

> Inovio sells off animal health assets to zero in on vaccines. Item

And Finally... The skeptical and cynical may be at higher risk for dementia. Report

Suggested Articles

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.

The departure of BMS' Paul Biondi, who presided over an extensive deal-making strategy, adds to the challenges presented by the Celgene integration.

Roche’s Tecentriq and Cotellic pairing went 0 for 1 in phase 3 melanoma trials—but Friday, they reversed that trend in a Zelboraf combo test.